Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Oklahoma City, OK
NPI: 1154434405Primary Practice Location
O U MEDICAL CENTER
1200 N Childrens Ave, Oklahoma City, OK
Primary Employer
OU Health Partners
ouhealth.com
HQ Phone
Get M.D. Adam's Phone NumberMobile
Get M.D. Adam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
OK State Medical License
OK State Medical License
2014 - 2025
NC State Medical License
2006 - 2015
NY State Medical License
1982 - 2008
American Board of Internal Medicine
Internal Medicine
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
New York Presbyterian Hospital (Cornell Campus)
Fellowship • Hematology and Medical Oncology
1982 - 1984
Zucker School of Medicine at Hofstra/Northwell
Residency • Internal Medicine
1979 - 1982
Swarthmore College
BA
—
Sidney Kimmel Medical College
jefferson.edu
Medical School
Until 1979
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 99 | 164 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 63 | 327 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 32 | 37 |
| 4 | 99214Established patient office or other outpatient visit, 30-39 minutes | 31 | 37 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 21 | 21 |
Authors: Sigounas, George, Hairr, Jonathan W, Cooke, Charles D, Owen, Jennifer R, Asch, Adam S, Weidner, Douglas A, Wiley, John E
Journal: Free Radic Biol Med
Publication Date: 2010-03-25
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Authors: Natalie Grover, Oludamilola Olajide, Matthew Foster
Publication Date: 2016-01-26
Lead Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Intervention / Treatment: BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + venetoclax, BIOLOGICAL: JCAR017 (lisocabtagene maraleucel), BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + ibrutinib
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Cancer Research UK, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Irish Group CTI
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: paclitaxel, DRUG: ifosfamide, DRUG: G-CSF, DRUG: etoposide phosphate, DRUG: pegylated G-CSF, PROCEDURE: stem cell reinfusion
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Docetaxel, DRUG: Ramucirumab
